EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Target-specific cardiotoxicity of tyrosine kinase inhibitors: a Systematic Review and meta-analysis

Zhe Wang, Zhiling Cheng, Yifan Zheng, Yang Liu, Zhihan Zhang, Yuan Gao, Congxin Li

Frontiers in Pharmacology · 23.07.2026 · 17

DOI: 10.3389/fphar.2026.1807099 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 23.07.2026. Verfasst von Zhe Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, China. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the association between different tyrosine kinase inhibitors (TKIs) and the risk of major adverse cardiovascular events (MACE). Data sources PubMed, the Cochrane Library, Embase, WanFang Data, and CNKI were searched for randomized controlled trials (RCTs) from inception to June 2026.

Results

A total of 25 RCTs met the inclusion criteria, encompassing 9,068 patients. The risk of MACE was significantly higher in the TKI-treated group than in the control group (odds ratio [OR] = 2.13; 95% confidence interval [CI], 1.11–4.07; P = 0.02). The ORs for QT prolongation, hypertension, and arrhythmias were 6.05 (95% CI, 3.70–9.89; P < 0.00001), 4.18 (95% CI, 2.19–7.95; P < 0.0001), and 5.40 (95% CI, 3.43–8.50; P < 0.00001), respectively. Subgroup analysis indicated that epidermal growth factor receptor inhibitors (EGFR-TKIs) were associated with the highest risk of cardiovascular adverse events, followed by vascular endothelial growth factor receptor inhibitors (VEGFR-TKIs), platelet-derived growth factor receptor inhibitors (PDGFR-TKIs), and stem cell factor receptor inhibitors (c-Kit TKIs).

Conclusion

TKI therapy significantly prolongs progression-free survival. However, the incidence of cardiovascular adverse events, including QT prolongation, hypertension, and arrhythmias, is notably higher with TKI use. EGFR-TKIs show the highest cardiovascular risk, followed by VEGFR-TKIs, PDGFR-TKIs, and c-Kit TKIs. Clinicians should be aware of these risks and ensure regular cardiovascular monitoring during treatment. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420251084805 , identifier CRD420251084805.

Schlagwörter

Stichwörter der Autor:innen

TKIscardiovascular adverse eventsmajor adverse cardiovascular eventsmeta-analysistarget

Autor:innen und Institutionen

  • Department of Pharmacy, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, China.
  • Hebei Medical University, Shijiazhuang, Hebei, China.
  • Department of Nutrition, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Hebei Provincial Key Laboratory of Precision Anesthesiology and Organ Protection, Shijiazhuang, China.

Zitieren

APA

Wang, Z., Cheng, Z., Zheng, Y., Liu, Y., Zhang, Z., Gao, Y., & Li, C. (2026). Target-specific cardiotoxicity of tyrosine kinase inhibitors: a Systematic Review and meta-analysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1807099

Vancouver

Wang Z, Cheng Z, Zheng Y, Liu Y, Zhang Z, Gao Y, et al. Target-specific cardiotoxicity of tyrosine kinase inhibitors: a Systematic Review and meta-analysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1807099

BibTeX
@article{Wang2026,
  author = {Wang, Zhe and Cheng, Zhiling and Zheng, Yifan and Liu, Yang and Zhang, Zhihan and Gao, Yuan and Li, Congxin},
  title = {Target-specific cardiotoxicity of tyrosine kinase inhibitors: a Systematic Review and meta-analysis},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1807099}
}
Kostenlos starten →